NeuroBo Pharmaceuticals (NRBO) announced the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist for the treatment of metabolic dysfunction-associated steatohepatitis. Topline data readout from part 1 and part 2 is expected in December.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.